New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder

Leslie Citrome, Bradley N. Gaynes, Joseph F. Goldberg, Terence Ketter, James W. Murrough

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Listen to experts and view their slides from a panel session at the American Society of Clinical Psychopharmacology (ASCP) meeting, held on May 29, 2019, in Scottsdale, Arizona. Dr Murrough described the current understanding of depression etiology and new insights into antidepressant development. Dr Goldberg shared his expertise about whether antidepressant drugs with novel mechanisms of action can improve outcomes in patients with major depressive disorder. Dr Gaynes reviewed the link between major depressive disorder and elevated mortality risk and whether recovery from depression can reverse patients' mortality risk. Dr Citrome discussed current best practices and new medications for the treatment of depression. Finally, Dr Ketter provided his thoughts on his colleagues' presentations.

Original languageEnglish
JournalJournal of Clinical Psychiatry
Volume80
Issue number5
DOIs
StatePublished - 30 Jul 2019

Fingerprint

Dive into the research topics of 'New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder'. Together they form a unique fingerprint.

Cite this